About: Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study
Creator	Miyazaki, Yasunari Fujiwara, Takeo Yamaoka, Yui Kuramochi, Jin Nawa, Nobutoshi Nukui, Yoko Sonoda, Shiro
Source	MedRxiv
abstract	Background: The number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan are substantially lower in comparison to the US and UK, potentially due to the under-implementation of polymerase chain reaction (PCR) tests. Studies reported that more than half of the SARS-CoV-2 infections are asymptomatic, confirming the importance for conducting seroepidemiological studies. Although the seroepidemiological studies in Japan observed a reported prevalence of 0.10% in Tokyo, 0.17% in Osaka, and 0.03% in Miyagi, sampling bias was not considered. The study objective was to assess the seroprevalence of SARS-CoV-2 in a random sample of households in Utsunomiya City in Tochigi Prefecture, Greater Tokyo, Japan. Methods: We launched the Utsunomiya COVID-19 seROprevalence Neighborhood Association (U-CORONA) Study to assess the seroprevalence of COVID-19 in Utsunomiya City. The survey was conducted between 14 June 2020 and 5 July 2020, in between the first and second wave of the pandemic. Invitations enclosed with a questionnaire were sent to 2,290 people in 1,000 households randomly selected from Utsunomiya basic resident registry. Written informed consent was obtained from all participants. The level of IgG antibodies to SARS-CoV-2 was assessed by chemiluminescence immunoassay analysis. Results: Among 2,290 candidates, 753 returned the questionnaire and 742 received IgG tests (32.4 % participation rate). Of the 742 participants, 86.8% were 18 years or older, 52.6% were women, 71.1% were residing within 10 km from the test clinic, and 89.2% were living with another person. The age and sex distribution, distance to clinic and police district were similar with those of non-participants, while the proportion of single-person households was higher among non-participants than participants (16.2% vs. 10.8%). We confirmed three positive cases through quantitative antibody testing. No positive cases were found among the people who live in the same household as someone with positive. All cases were afebrile. The estimated unweighted and weighted prevalence of SARS-CoV-2 infection were 0.40% (95% confidence interval: 0.08-1.18%) and 1.23% (95% confidence interval: 0.17-2.28%), respectively. Conclusion: This study suggests the importance of detecting all cases using PCR or antigen testing, not only at a hospital, but also in areas where people assemble. Further prospective studies using this cohort are needed to monitor SARS-CoV-2 antibody levels.
has issue date	2020-07-26(xsd:dateTime)
bibo:doi	10.1101/2020.07.20.20155945
has license	medrxiv
sha1sum (hex)	6dbe565e85a32fccee31cbecda4db86adeb0ea65
schema:url	https://doi.org/10.1101/2020.07.20.20155945
resource representing a document's title	Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study
resource representing a document's body	covid:6dbe565e85a32fccee31cbecda4db86adeb0ea65#body_text
is schema:about of	named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'assess' named entity 'polymerase' named entity 'LOWER' named entity 'TOCHIGI PREFECTURE' named entity 'SEROEPIDEMIOLOGICAL STUDIES' named entity 'POLYMERASE CHAIN REACTION' named entity 'SEROPREVALENCE' named entity 'GREATER' named entity 'HOUSEHOLD' named entity 'Japan' named entity 'objective' named entity 'sampling bias' named entity 'Greater' named entity 'SARS-CoV-2' named entity 'immunoassay' named entity 'Utsunomiya' named entity 'Osaka' named entity 'Shenzhen' named entity 'Tokyo Medical and Dental University' named entity '95% confidence interval' named entity 'informed consent' named entity 'seroprevalence' named entity 'College Station, TX' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'polymerase chain reaction' named entity 'Tochigi Prefecture' named entity 'sensitivity and specificity' named entity 'medRxiv' named entity 'CC-BY-NC-ND 4.0' named entity 'seroprevalence' named entity 'sampling bias' named entity 'questionnaire' named entity 'Los Angeles' named entity 'SARS-CoV-2' named entity 'Utsunomiya' named entity 'Japan' named entity 'COVID-19' named entity 'antibody' named entity 'seroprevalence' named entity 'prospective studies' named entity 'chemiluminescence' named entity 'Utsunomiya' named entity 'IgG antibodies' named entity 'Miyagi' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity 'seROprevalence' named entity 'medRxiv' named entity 'antigen' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'seroprevalence' named entity 'Shenzhen' named entity 'Tokyo' named entity 'medRxiv' named entity 'resident registry' named entity 'research ethics committee' named entity 'PCR' named entity 'China' named entity 'medRxiv' named entity 'medRxiv' named entity '95% confidence interval' named entity 'Utsunomiya' named entity 'Biotech' named entity 'PCR' named entity 'Japan' named entity 'SARS-CoV-2' named entity 'STATA' named entity 'random sample' named entity 'SARS-CoV-2' named entity 'assay' named entity 'seroprevalence' named entity 'afebrile' named entity 'Tokyo' named entity 'medRxiv' named entity 'antibody testing'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software